Indian company SAFFARM, a resident of the Arctic zone of the Russian Federation, will launch the production of import-substituting medicine in 2027.
The production facility, which will produce 1.3 billion units of general, oncological and hormonal drugs, will be located in Murmansk.
According to the agreement with the Corporation for the Development of the Far East and the Arctic, more than 9.2 billion rubles will be invested in the project, including Indian capital, 280 people will get jobs, ttelegraf.ru reports.
"We will be able to meet domestic Russian demand by supplying medicine to state hospitals and pharmacies, and, if necessary, we will be able to export about ten percent of the total production to the CIS countries," said Kumar Divesh, CEO of SAFFARM LLC.
The Minister of the Russian Federation for the Development of the Far East and the Arctic Alexey Chekunkov noted that the state support measures created for residents of the Arctic have equally favorable conditions for both Russian and foreign investors.
Currently, 645 projects with investments of 817 billion rubles are being implemented in the Arctic, creating more than 24 300 new jobs. Residents of the Arctic zone of the Russian Federation are building fitness centers, camp sites, hotels in the Arctic. With the support of the Norilsk Development Agency 22 entrepreneurs became residents of the Arctic.
Alex Shishlo for Rough&Polished
